While Inovio Pharmaceuticals Inc has overperformed by 2.16%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, INO fell by -22.40%, with highs and lows ranging from $12.33 to $1.30, whereas the simple moving average fell by -47.70% in the last 200 days.
On July 09, 2025, Piper Sandler started tracking Inovio Pharmaceuticals Inc (NASDAQ: INO) recommending Overweight. A report published by Stephens on May 14, 2024, Initiated its previous ‘Overweight’ rating for INO. Oppenheimer also Upgraded INO shares as ‘Outperform’, setting a target price of $4 on the company’s shares in a report dated January 25, 2024. BofA Securities November 01, 2022d its ‘Neutral’ rating to ‘Underperform’ for INO, as published in its report on November 01, 2022. RBC Capital Mkts’s report from July 19, 2022 suggests a price prediction of $4 for INO shares, giving the stock a ‘Sector Perform’ rating. Oppenheimer also rated the stock as ‘Perform’.
Analysis of Inovio Pharmaceuticals Inc (INO)
There are several well-rounded types of analysis and research techniques that can be used to gain a clear view of Inovio Pharmaceuticals Inc’s future performance, with equity being one of the most critical indicators. The goal here is to ensure that your current return on equity of -132.44% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 2.63, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
As an indicator of volatility for any stock, average volume can also be very valuable, and INO is recording an average volume of 1.44M. On a monthly basis, the volatility of the stock is set at 7.60%, whereas on a weekly basis, it is put at 4.98%, with a gain of 4.41% over the past seven days. Furthermore, long-term investors anticipate a median target price of $7.50, showing growth from the present price of $1.42, which can serve as yet another indication of whether INO is worth investing in or should be passed over.
How Do You Analyze Inovio Pharmaceuticals Inc Shares?
Apart from looking at the fundamentals, you should also pay attention to the number of company employees who own shares. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 0.79%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 26.69% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
INO shares are owned by institutional investors to the tune of 26.69% at present.
